Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04/24JOHNSON & JOHNSON : to Participate in the 2018 Deutsche Bank 43rd Annual Health ..
PR
04/24Robotic Surgical Systems Market Analysis Trend, Growth, Volume, Size and Dema..
AQ
04/24JOHNSON & JOHNSON : Tessy Plastics, Avery Dennison and EcoVadis Advise Companies..
AQ
04/24ADVAXIS, INC. (NASDAQ : ADXS) Files An 8-K Departure of Directors or Certain Off..
AQ
04/21JOHNSON & JOHNSON : J&J, BMS Team Up on Cardiovascular Therapies
AQ
04/20GENMAB : Announces Net Sales of DARZALEX for First Quarter of 2018
AQ
04/20JOHNSON & JOHNSON : Reports 2018 First-Quarter Results
AQ
04/20JOHNSON & JOHNSON : Janssen Announces Worldwide Development and Commercializatio..
AQ
04/20JOHNSON & JOHNSON : Janssen Pharmaceutical - Newly Published Phase 2 Study Found..
AQ
04/20JOHNSON & JOHNSON : Small biotech companies dominate the pipeline for Microbiome..
AQ
More news
News from SeekingAlpha
04/24MONTHLY REVIEW OF DIVGRO : March 2018 
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/23CELGENE : Bold Pursuits In Science With 24.66% Discount 
04/23GENERAL ELECTRIC : Buy On The Dip Opportunity 
04/23RETIREMENT STRATEGY : Waiting For Some Good Buys? Here Are A Few 
Financials ($)
Sales 2018 81 509 M
EBIT 2018 24 881 M
Net income 2018 16 279 M
Debt 2018 9 501 M
Yield 2018 2,85%
P/E ratio 2018 18,69
P/E ratio 2019 17,11
EV / Sales 2018 4,29x
EV / Sales 2019 4,01x
Capitalization 340 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 145 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.13%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398
AMGEN0.44%116 720